• Alzheimer's
  • This Phase 1b clinical trial will examine the safety and effectiveness of oxaloacetate as an alternative energy source to improve brain function in individuals with Alzheimer's disease. (alz.org)
  • Russell Swerdlow, M.D., and colleagues have proposed a clinical trial of oxaloacetate as a possible substitute energy source for the brain in individuals with mild-to-moderate Alzheimer's disease. (alz.org)
  • If effective, this study could lead to further clinical trials of oxaloacetate in people who have Alzheimer's disease with the goal to slow, or stop disease progression. (alz.org)
  • groups
  • The 19F n.m.r. line-width-pH and chemical-shift-pH profiles of difluoro-oxaloacetate in the presence of the aldimine form of the enzyme both show inflexion points in the pH5 and pH8 regions, which may arise from variations in the binding of difluoro-oxaloacetate as specific groups on the enzyme are successively protonated. (biochemj.org)
  • brain
  • The researchers also will use brain imaging to examine how oxaloacetate is taken up and used in the brain. (alz.org)